Drug Profile

Gallium-68 NRT 6020 - Chengdu New Radiomedicine Technology

Alternative Names: ⁶⁸GaNRT6020

Latest Information Update: 30 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chengdu New Radiomedicine Technology
Class Antineoplastics; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
Mechanism of Action Fibroblast activation protein antagonists; Positron-emission tomography enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

04 Apr 2025 Preclinical trials in Solid tumours (Diagnosis) in China (IV)
04 Apr 2025 Chengdu New Radiomedicine Technology plans a phase I trial for Solid tumours (Late-stage disease, Diagnosis) in July 2025 (IV) (NCT06911489)
01 Jan 2025 Chengdu New Radiomedicine Technology submits clinical trial application in China and the US prior to March 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com